Resolution of severe MMF-related gastrointestinal adverse events following conversion to enteric-coated mycophenolate sodium [1]

Transplantation

Volumn 79, Issue 8, 2005, Pages 987-988

  Suwelack, Barbara ^a   Gabriels, Gert ^a   Volmer, Sabine ^a   Hillebrand, Uta ^a   Hohage, Helge ^a   Pohle, Thorsten ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL DISCOMFORT; ADULT; APPETITE DISORDER; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; DIARRHEA; DRUG COATING; DRUG DOSE REDUCTION; DRUG FORMULATION; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LETTER; MALE; NAUSEA; PRIORITY JOURNAL;

ADULT; FOLLOW-UP STUDIES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; STOMACH ULCER;

EID: 17844368383     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000154917.80349.00     Document Type: Letter

References (5)

1. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231.
2. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5: 1333.
3. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
4. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
5. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237.